A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Trial Profile

A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Buparlisib (Primary) ; Rituximab
  • Indications B cell lymphoma; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 06 Dec 2016 Results of safety and preliminary efficacy (n=14) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top